MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
2.320
+0.320
+16.00%
After Hours: 2.288 -0.032 -1.38% 19:54 03/09 EDT
OPEN
1.980
PREV CLOSE
2.000
HIGH
2.470
LOW
1.975
VOLUME
4.95M
TURNOVER
--
52 WEEK HIGH
4.537
52 WEEK LOW
0.9101
MARKET CAP
226.48M
P/E (TTM)
-0.9768
1D
5D
1M
3M
1Y
5Y
1D
Editas Medicine Price Target Maintained With a $3.50/Share by Chardan Capital
Dow Jones · 9h ago
Editas Medicine Is Maintained at Buy by Chardan Capital
Dow Jones · 9h ago
Editas Medicine Shares Jump on Narrower 4Q Loss, Revenue Beat
Dow Jones · 13h ago
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 16h ago
Editas Medicine Q4 Earnings Assessment
Benzinga · 16h ago
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate
Benzinga · 17h ago
Editas Medicine posts smaller‑than‑expected Q4 net loss on lower R&D spend
Reuters · 17h ago
Editas Medicine reports Q4 EPS (6c), consensus (26c)
TipRanks · 17h ago
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.